version française rss feed
Fiche concise
STEAP1 is overexpressed in cancers: A promising therapeutic target.
Moreaux J., Kassambara A., Hose D., Klein B.
Biochemical and Biophysical Research Communications (2012) epub ahead of print - http://www.hal.inserm.fr/inserm-00760262
STEAP1 is overexpressed in cancers: A promising therapeutic target.
Jérôme Moreaux () 1, 2, Alboukadel Kassambara1, Dirk Hose3, Bernard Klein1, 2
1 :  Cellules souches normales et cancéreuses
INSERM : U1040 – Institut de recherche en biothérapie – Université Montpellier I
Hôpital Saint-Eloi, 80 av Augustin Fliche 34295 Montpellier Cedex 15
2 :  IRB - Institut de recherche en biothérapie
CHRU Montpellier – Université Montpellier I
Hôpital Saint-Eloi 34000 Montpellier
3 :  Department of Internal Medicine V
University of Heidelberg
Seminarstr. 2, 69117 Heidelberg
The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in advanced prostate cancer and is up-regulated in multiple cancer cell lines, including prostate, bladder, colon, ovarian, and Ewing sarcoma. STEAP1 was described as a suitable antigen for T-cell-based or antibody-based immunotherapy. We have investigated the expression of STEAP1 in 40 human tumor types - brain, epithelial, lymphoid - and in their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database. STEAP1 was found significantly overexpressed in 11 cancers. In addition, high STEAP1 expression was associated with poor overall survival in colorectal cancer, diffuse large B cell lymphoma, acute myeloid leukemia and multiple myeloma. Taken together, these data suggest that STEAP1 is a potential therapeutic target for T-cell based immunotherapy or antibody therapy in a large panel of cancers.
Sciences du Vivant/Immunologie

Articles dans des revues avec comité de lecture
Biochemical and Biophysical Research Communications (Biochem Biophys Res Commun)
Publisher Elsevier
ISSN 0006-291X (eISSN : 1090-2104)
epub ahead of print

STEAP1 – Gene expression profiling – Cancer
ARC (SL220110303450, Paris, France; FEDER (141786 et 42667); INCA Canceropole GSO (2012-011); Hopp-Foundation Germany
Acronyme FP7 OverMyr
Liste des fichiers attachés à ce document : 
Papier_STEAP1_HAL_Inserm.pdf(1.6 MB)